1. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and fungal co-infection in individuals with coronavirus: A rapid review to support COVID-19 antimicrobial prescribing. Clin Infect Dis. published online May 2 (2020). DOI: 10.1093/cid/ciaa530.
2. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 323, 1061-9 (2020).
3. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. J Med Virol. published online Mar 12 (2020).
DOI: 10.1002/jmv.25757.
4. Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. published online Mar 20 (2020). DOI: 10.1016/j.ijantimicag.2020.105949.
5. Zheng YX, Chen J, Kong DC, et al. [Pathogenic characteristics of hospitalized severe acute respiratory infections in Shanghai, China, 2015-2017]. Zhonghua Liu Xing Bing Xue Za Zhi. 40, 911-916 (2019). (in Chinese)
6. Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 323, 2052-9 (2020).
7. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. JAMA. published online Feb 24 (2020).
DOI: 10.1001/jama.2020.2648.
8. Mason S, Devincenzo JP, Toovey S, Wu JZ, Whitley RJ. Comparison of antiviral resistance across acute and chronic viral infections. Antiviral Res. 158, 103-12 (2018).
9. Reardon S. Antibiotic treatment for COVID-19 complications could fuel resistant bacteria. 2020. https://www.sciencemag.org/news/2020/04/antibiotic-treatment-covid-19-complications-could-fuel-resistant-bacteria (accessed May 1, 2020)